Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer.

Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, Rosenfeld JA, Cox AG, Hedgepeth J, Wucherpfennig JI, Kim AJ, Henderson JE, Gonyo P, Brandt A, Lorimer E, Unger B, Prokop JW, Heidel JR, Wang XX, Ukaegbu CI, Jennings BC, Paulo JA, Gableske S, Fierke CA, Getz G, Sunyaev SR, Wade Harper J, Cichowski K, Kimmelman AC, Houvras Y, Syngal S, Williams C, Goessling W.

Nat Genet. 2019 Sep;51(9):1308-1314. doi: 10.1038/s41588-019-0475-y. Epub 2019 Aug 12.

PMID:
31406347
2.

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas.

Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, Wong TC, De Raedt T, Bowman-Colin C, Hatchi E, Garraway LA, Flaherty KT, Pathania S, Elledge SJ, Cichowski K.

Cancer Discov. 2019 Apr;9(4):526-545. doi: 10.1158/2159-8290.CD-18-0879. Epub 2019 Feb 1.

PMID:
30709805
3.

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.

Liao S, Maertens O, Cichowski K, Elledge SJ.

Genes Dev. 2018 Sep 1;32(17-18):1188-1200. doi: 10.1101/gad.315648.118. Epub 2018 Aug 22.

4.

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, Sproesser K, Herlyn M, Adams DJ, Locasale JW, Cichowski K, Mukherjee S, Wood KC.

Cell Rep. 2017 Dec 5;21(10):2796-2812. doi: 10.1016/j.celrep.2017.11.022.

5.

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K.

Cancer Res. 2017 Nov 1;77(21):5706-5711. doi: 10.1158/0008-5472.CAN-17-1789. Epub 2017 Oct 9. Review.

6.

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.

Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S, Yoon H, Liu LL, Michor F, Haigis M, Macleod KF, Maertens O, Cichowski K.

Cancer Discov. 2017 Dec;7(12):1450-1463. doi: 10.1158/2159-8290.CD-17-0177. Epub 2017 Sep 29.

7.

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.

Lock R, Ingraham R, Maertens O, Miller AL, Weledji N, Legius E, Konicek BM, Yan SC, Graff JR, Cichowski K.

J Clin Invest. 2016 Jun 1;126(6):2181-90. doi: 10.1172/JCI85183. Epub 2016 May 9.

8.

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A.

Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042.

9.

Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.

Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K.

Cancer Discov. 2014 Sep;4(9):1062-73. doi: 10.1158/2159-8290.CD-14-0159. Epub 2014 Jun 9.

10.

An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer.

Maertens O, Cichowski K.

Adv Biol Regul. 2014 May;55:1-14. doi: 10.1016/j.jbior.2014.04.002. Epub 2014 Apr 30. Review.

PMID:
24814062
11.

Paths of resistance to EGFR inhibitors: is NF enough?

Maertens O, Cichowski K.

Cancer Discov. 2014 May;4(5):519-21. doi: 10.1158/2159-8290.CD-14-0286.

12.

Elucidating distinct roles for NF1 in melanomagenesis.

Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K.

Cancer Discov. 2013 Mar;3(3):338-49. doi: 10.1158/2159-8290.CD-12-0313. Epub 2012 Nov 21.

13.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.

Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7.

14.

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K.

Cancer Cell. 2011 Sep 13;20(3):400-13. doi: 10.1016/j.ccr.2011.08.014.

15.

Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association.

Brems H, Park C, Maertens O, Pemov A, Messiaen L, Upadhyaya M, Claes K, Beert E, Peeters K, Mautner V, Sloan JL, Yao L, Lee CC, Sciot R, De Smet L, Legius E, Stewart DR.

Cancer Res. 2009 Sep 15;69(18):7393-401. doi: 10.1158/0008-5472.CAN-09-1752. Epub 2009 Sep 8. Erratum in: Cancer Res. 2009 Oct 15;69(20):8216. Messia, Ludwine [corrected to Messiaen, Ludwine].

16.

Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes.

De Schepper S, Maertens O, Callens T, Naeyaert JM, Lambert J, Messiaen L.

J Invest Dermatol. 2008 Apr;128(4):1050-3. Epub 2007 Oct 4. No abstract available.

17.

Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1.

Maertens O, De Schepper S, Vandesompele J, Brems H, Heyns I, Janssens S, Speleman F, Legius E, Messiaen L.

Am J Hum Genet. 2007 Aug;81(2):243-51. Epub 2007 Jun 20.

18.

Real-time quantitative allele discrimination assay using 3' locked nucleic acid primers for detection of low-percentage mosaic mutations.

Maertens O, Legius E, Speleman F, Messiaen L, Vandesompele J.

Anal Biochem. 2006 Dec 1;359(1):144-6. Epub 2006 Aug 14. No abstract available.

PMID:
16962063
19.

Comprehensive NF1 screening on cultured Schwann cells from neurofibromas.

Maertens O, Brems H, Vandesompele J, De Raedt T, Heyns I, Rosenbaum T, De Schepper S, De Paepe A, Mortier G, Janssens S, Speleman F, Legius E, Messiaen L.

Hum Mutat. 2006 Oct;27(10):1030-40.

PMID:
16941471
20.

Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients.

De Raedt T, Maertens O, Chmara M, Brems H, Heyns I, Sciot R, Majounie E, Upadhyaya M, De Schepper S, Speleman F, Messiaen L, Vermeesch JR, Legius E.

Genes Chromosomes Cancer. 2006 Oct;45(10):893-904.

PMID:
16830335
21.

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients.

Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, De Wever I, Vermeesch JR, de Raedt T, De Paepe A, Speleman F, van Oosterom A, Messiaen L, Legius E.

Hum Mol Genet. 2006 Mar 15;15(6):1015-23. Epub 2006 Feb 6.

PMID:
16461335
22.

Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients.

Wimmer K, Yao S, Claes K, Kehrer-Sawatzki H, Tinschert S, De Raedt T, Legius E, Callens T, Beiglböck H, Maertens O, Messiaen L.

Genes Chromosomes Cancer. 2006 Mar;45(3):265-76.

PMID:
16283621
23.

Independent NF1 mutations in two large families with spinal neurofibromatosis.

Messiaen L, Riccardi V, Peltonen J, Maertens O, Callens T, Karvonen SL, Leisti EL, Koivunen J, Vandenbroucke I, Stephens K, Pöyhönen M.

J Med Genet. 2003 Feb;40(2):122-6. No abstract available.

Supplemental Content

Loading ...
Support Center